Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MIGUEL A CHAMAH-FARRE

Allopathic & Osteopathic Physicians General Practice

NPI
1912914698
CMS profile
131855
Location
HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,319.37

77 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,307.57 75
Education $11.80 2

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 77 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MIGUEL A CHAMAH-FARRE

NPI 1912914698 · CMS profile ID 131855

Allopathic & Osteopathic Physicians / General Practice

HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 77 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912914698?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MIGUEL A CHAMAH-FARRE, NPI 1912914698, CMS profile ID 131855. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 77 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912914698?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MIGUEL A CHAMAH-FARRE, NPI 1912914698, CMS profile ID 131855. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 77 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912914698?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MIGUEL A CHAMAH-FARRE, NPI 1912914698, CMS profile ID 131855, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 77 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1912914698?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

77 matching records · $2,319.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 77 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 77.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $16.4312/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708842787 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.7112/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700429627 CMS
Zyla Life Sciences $16.4712/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704842729 CMS
Radius Health, Inc. $78.4912/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683967839 CMS
Kowa Pharmaceuticals America, Inc. $17.2811/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 630260281 CMS
Radius Health, Inc. $17.1711/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683967821 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.0911/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700429629 CMS
Lilly USA, LLC $16.3511/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658035805 CMS
Janssen Pharmaceuticals, Inc $18.5211/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658413185 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.5411/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700429631 CMS
Novartis Pharmaceuticals Corporation $120.3611/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659066461 CMS
Zyla Life Sciences $21.1511/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704848083 CMS
Amarin Pharma Inc. $14.8810/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699231433 CMS
Amgen Inc. $22.5609/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662787083 CMS
AstraZeneca Pharmaceuticals LP $18.0609/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685504787 CMS
Novartis Pharmaceuticals Corporation $20.8209/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659066457 CMS
Edwards Lifesciences Corporation $125.0009/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700782093 CMS
AbbVie, Inc. $119.9109/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648031965 CMS
Amgen Inc. $16.3809/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662787096 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.8009/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700429633 CMS
Lilly USA, LLC $16.5008/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658036557 CMS
Lilly USA, LLC $75.0008/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658050351 CMS
Lilly USA, LLC $7.5008/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658053781 CMS
Abbott Laboratories $128.9608/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665917087 CMS
Zyla Life Sciences $15.7508/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704842461 CMS
Janssen Pharmaceuticals, Inc $16.4708/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658413181 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.0908/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700429635 CMS
Amarin Pharma Inc. $17.8508/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699192489 CMS
Amarin Pharma Inc. $5.9008/08/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699197675 CMS
AstraZeneca Pharmaceuticals LP $16.3408/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685421869 CMS
Novartis Pharmaceuticals Corporation $15.0107/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659066448 CMS
Amgen Inc. $14.5607/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662787093 CMS
Astellas Pharma US Inc $18.0107/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655498583 CMS
SANOFI-AVENTIS U.S. LLC $124.9907/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694138577 CMS
Amarin Pharma Inc. $124.2007/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699182571 CMS
Novo Nordisk Inc $15.1707/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674498575 CMS
Merck Sharp & Dohme Corporation $17.9307/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695660905 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.3306/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700056805 CMS
Zyla Life Sciences $13.2306/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704850679 CMS
Kowa Pharmaceuticals America, Inc. $19.5506/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 630260279 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.7206/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700429637 CMS
PFIZER INC. $14.8306/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673297881 CMS
Novartis Pharmaceuticals Corporation $15.4606/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659066441 CMS
Lilly USA, LLC $78.0005/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658032593 CMS
Lilly USA, LLC $13.2605/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658032595 CMS
Lilly USA, LLC $6.2405/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658040047 CMS
Janssen Pharmaceuticals, Inc $14.3205/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658413179 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.5705/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700429639 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.2105/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684685203 CMS
Horizon Therapeutics plc $16.8205/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691347143 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,319.37 77
PY2020 $1,354.03 46
PY2021 $2,508.56 34
PY2022 $1,125.21 15
PY2023 $264.88 8
PY2024 $590.16 13
PY2025 $664.62 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $44,007.04 7
PY2024 Principal investigator $10,995.00 3
PY2023 Principal investigator $40,870.70 2
PY2022 Principal investigator $8,245.00 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 09/19/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947290411
Principal investigator 1 Esperion Therapeutics, Inc. $48.00 09/19/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947290417
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287883
Principal investigator 1 Esperion Therapeutics, Inc. $1,370.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287889
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287895
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287901
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287907
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287911
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287917
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287923
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287929
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287935
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287941
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287947
Principal investigator 1 Esperion Therapeutics, Inc. $1,370.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287953
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287959
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287965
Principal investigator 1 Esperion Therapeutics, Inc. $48.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287971
Principal investigator 1 Esperion Therapeutics, Inc. $48.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287977
Principal investigator 1 Esperion Therapeutics, Inc. $48.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287983
Principal investigator 1 Esperion Therapeutics, Inc. $500.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287989
Principal investigator 1 Esperion Therapeutics, Inc. $500.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947287995
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947288001
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947288007
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947288011
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947288017
Principal investigator 1 Esperion Therapeutics, Inc. $227.00 08/23/2022 Non-covered Recipient Entity
Q-WAY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947288023